Ignite Creation Date:
2024-05-05 @ 11:37 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00098865
Status:
COMPLETED
Last Update Posted:
2014-10-07
First Post:
2004-12-08
Brief Title:
Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
01-279 DFCI
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Dana-Farber Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
Mark W Kieran MD PhD
Responsible Party Title:
Principal Investigator
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Dana-Farber Cancer Institute
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Celgene Corporation | INDUSTRY |
| National Cancer Institute NCI | NIH |
| Boston Childrens Hospital | OTHER |